[5]
Snell, E.E. The vitamin activities of pyridoxal and pyridoxamine. J. Biol. Chem., 1944, 315, 313-315.
[10]
McCormick, D.B. Pyridoxine, Encycl, 3rd ed; Toxicol, 2014, pp. 1165-1166.
[36]
Fox, E.; Ridgewell, A.; Ashwin, C. Looking on the bright side: Biased attention and the human serotonin transporter gene. Proc. R. Soc. B Biol. Sci., 2009, 276, 1747-1751.
[39]
Abali, E.E.; Skacel, N.E.; Celikkaya, H.; Hsieh, Y.C. Regulation of human dihydrofolate reductase activity and expression. Vitam. Horm., 2008, 79, 267-292.
[41]
Kamen, B. Folate and antifolate pharmacology. Semin. Oncol., 1997, 24(5 Suppl 18), S18-30-S18-39.
[42]
Brown, R.R.; Rose, D.P.; Leklem, J.E.; Linkswiler, H.M. Effects of oral contraceptives on tryptophan metabolism and vitamin B6 requirements in women. Acta Vitaminol. Enzymol., 1975, 29(1-6), 151-157.
[43]
William, F.S. Fundamental role of methylenetetrahydrofolate reductase 677 C → T genotype and flavin compounds in biochemical phenotypes for schizophrenia and schizoaffective psychosis. Front. Psychiatry, 2016, 7, 172.
[46]
Chiang, P.K.; Gordon, R.K.; Tal, J.; Zeng, G.C.; Doctor, B.P.; Pardhasaradhi, K.; McCann, P.P. S-Adenosylmethionine methylation. FASEB J., 1996, 10(4), 471-480.
[48]
Di Salvo, M.L.; Safo, M.K.; Contestabile, R. Biomedical aspects of pyridoxal 5′-phosphate availability. Front. Biosci., 2012, 4(3), 897-913.
[54]
Haque, W. Pyridoxine AMD pyridoxal analogues: Cardiovascular therapeutics. Patent no. US6417204B1, 2002.
[55]
Haque, W.; Diakur, J.; Pham, V.; Zhang, W. Substitued pyridoxines as anti-platelet agents. WO2006045203A1, 2006.
[56]
Haque, W. Pyridoxine and pyridoxine analogues. JP2004502757A, 2004.
[69]
Diakur, J.; Haque, W.; Pham, V.; Yao, J.; Zhang, W. Novel heteroaryl phosphonates as cardioprotective agents. US2006241083A1,
[72]
Shtyrlin, Y.G.; Dzyurkevich, M.S.; Shtyrlin, N.V.; Gerasimova, E.V.; Iksanova, A.G.; Sitdikova, G.F.; Yakovlev, A.V. Pyridoxine derivative for treatment of epilepsy. US10844018B2, 2020.
[81]
Shtyrlin, Y.G.; Pavel'Ev, R.S.; Iksanova, A.G.; Shtyrlin, N.V.; Pugachev, M.V.; Balakin, K.V.; Ajmaletdinov, A.M.; Ganiev, I.M. Malan'Eva, A.G. Naproxen-based non-steroidal anti-inflammatory drug with low gastric toxicity. US10507202B2, 2019.
[82]
Mibielli, M.A.; Geller, M.; Cohen, J.C.; Goldberg, S.G.; Cohen, M.T.; Nunes, C.P.; Oliveira, L.B.; Da Fonseca, A.S. Diclofenac plus B vitamins versus diclofenac monotherapy in lumbago: The DOLOR study. Curr. Med. Res. Opin., 2009, 25(11), 2589-99.
[89]
Haque, W. Pyridoxal Analogues for vitamin B-6 disorders. WO0053606A1, 2000.
[90]
Haque, W. Cardioprotective phosphonates and malonates. WO0164692A1, 2001.
[91]
Essanu, A. Furo-(3,4-C)-pyridine derivatives and therapeutic composition containing the same. US4735950A, 1988.
[92]
Ibrahim, M.A. Evaluating the Effect of PIH on Rats-Liver Overloaded with Iron, 2016, 11, 73-82.
[93]
Richardson, D.; Kalinowski, D.S.; Palanimuthu, D. Palanimuthu, adamantane compounds. WO2017214680A1, 2017.
[94]
Sarel, S. Pyridoxal hydrazone derivatives their production and use and pharmaceutical compositions containing the same. EP0315434A2, 1989.
[96]
Diana, G.D.; Bailey, T.R.; Young, D.C.; Chunduru, S.K. Compositions and methods for treating or preventing viral infections and associated diseases. WO03090674A2, 2003.
[97]
Stanek, J.; Caravatti, G.; Frei, J.; Capraro, H.G. Substituted oxadiaminobutane. EP0369944A1, 1989.